As of 2018, there are 7,000 types of rare diseases recognised in the world. In 1983 the Orphan Drug Act was passed in the United States to facilitate drugs for rare diseases that afflicted small number of individuals. To many who are unfamiliar, drugs are commonly catered to facilitate the majority. This is due to factors such as funding, relevance and demand. But all that is gradually changing as more unknown diseases or, to be politically correct ‘conditions’, are coming to the forefront calling for new attention.